anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Therapy 177Lu DOTATATE, total activity 4x5.55GBq (22.2 GBq), i.v. infusion of 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids solution (AA) 1000ml for 1h before and then et least 6h after 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other or therapy 90Y and 177Lu DOTATATE, 4x3.7GBq total activity 14.8 GBq, (mix 50% each 90Y and 177Lu), i.v. infusion of mix 90Y and 177Lu DOTATATE administered for 20 min via infusion pump with co-infusion of amino-acids (AA) solution 1000ml for 1h before and then et least 6h after 90Y and 177Lu DOTATATE infusion. Therapy consists up to 4 cycles at 8 ± 2 weeks between each other.
PURPOSE: Overactive bladder (OAB) syndrome significantly impairs quality of life, often necessitating pharmacological interventions with associated risks. The fragility of OAB trial outcomes, as measured by the fragility index (FI: smallest number of event changes to reverse statistical significance) and quotient (FQ: FI divided by total sample size expressed as a percentage), is critical yet unstudied.
MATERIALS AND METHODS: We conducted a systematic search for randomized controlled trials on OAB medications published between January 2000 and August 2023. Inclusion criteria were trials with two parallel arms reporting binary outcomes related to OAB medications. We extracted trial details, outcomes, and statistical tests employed. We calculated FI and FQ, analyzing associations with trial characteristics through linear regression.
RESULTS: We included 57 trials with a median sample size of 211 participants and a 12% median lost to follow-up. Most studies investigated anticholinergics (37/57, 65%). The median FI/FQ was 5/3.5%. Larger trials were less fragile (median FI 8; FQ 1.0%) compared to medium (FI: 4; FQ 2.5%) and small trials (FI: 4; FQ 8.3%). Double-blinded studies exhibited higher FQs (median 2.9%) than unblinded trials (6.7%). Primary and secondary outcomes had higher FIs (median 5 and 6, respectively) than adverse events (FI: 4). Each increase in 10 participants was associated with a +0.19 increase in FI (p < 0.001).
CONCLUSIONS: A change in outcome for a median of five participants, or 3.5% of the total sample size, could reverse the direction of statistical significance in OAB trials. Studies with larger sample sizes and efficacy outcomes from blinded trials were less fragile.
Mammary analogue secretory carcinoma (MASC) is a rare salivary gland tumor which shares its histologic, immunohistochemical, and genetic features with the secretory carcinoma (SC) of breast. In this case report, we describe a case of MASC in a young adolescent male with swelling in the right angle of mandible which is a relatively rare site to present along with its correlation of cytological, histological, and immunohistochemical features. A 16-year-old male came with the complaint of swelling in the right angle of mandible since 2 years. Contrast-enhanced computed tomography (CECT) neck revealed differential diagnosis of nerve sheath tumor, pleomorphic adenoma, and adenoid cystic neoplasm was kept, and subsequently fine-needle aspiration cytology (FNAC) was done. FNAC was done in which differential diagnosis of myoepithelial neoplasm, acinic cell carcinoma, and SC was given. Surgical excision was done followed by histopathological examination. Immunohistochemistry panel was also applied, and final diagnosis of SC was rendered. SC has distinct cytological, histological, and immunohistochemical features which should be recognized by the pathologists for the appropriate management of the patient.
CASE: A 51-year-old woman, who had previously undergone C5-C7 anterior cervical discectomy and fusion, presented with symptomatic hardware failure and subsequently underwent instrumentation removal. Her postoperative course was complicated by an esophageal perforation. Despite initial repair using a rotational flap, the leak persisted, prompting esophageal reconstruction with a radial forearm free flap (RFFF).
CONCLUSION: Persistent esophageal perforation is exceedingly rare and difficult to treat. This report discusses the surgical technique for RFFF, an excellent option for revising failed sternocleidomastoid rotational flaps. The decision between rotational repair and free flap reconstruction depends on factors such as defect size, vascularization, wound condition, and donor site morbidity.
FIELD: medicine. ^ SUBSTANCE: invention concerns experimental biology. The method involves taking a vegetable drug. The vegetable drug is a phytococktail which contains snowdone rose, eleuterococcus, common licorice and elfwort in the form of 70% alchoholates which are taken in the proportion 2:2:1:1 and dissolved in distilled water in the proportion 1:50. Phytococtails are taken through a probe of 1 ml according to animals chronotype within 16.00 to 18.00 o'clock for 15 days. ^ EFFECT: method allows improving peripheral microcirculation in healthy animals in experiment as well as reducing a risk of clinical and experimental cardiovascular complications. ^ 1 tbl
The treatment administration phase will consist of three (3) treatments, delivered once a week. The applicator of BTL-703 will be applied over the umbilicus. The active group will receive treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold. The device will induce visible muscle contractions along with heating of the subcutaneous fat.
Pneumonia patients with XDRAB are eligible for this multicenter study, do not meet the exclusion criteria and will sign the informed consent. They will received the anti-infection protocol with Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h). All enrolled patients were randomly divided into three groups according to the difference in pH value of aerosol inhalation with sodium bicarbonate solution. Group one is blank-control and patients will received usual antibiotic treatment without inhalation. The pH value in group two is 7.4 and that in group is 7.8. Each time the volume of aerosol solution is 5ml, q8h. The average course of treatment will be two weeks. Clinical indexes will be collected including vital signs, pulmonary rales, cough level, expectoration level, sputum color,blood count, arterial blood gas, biochemical parameters, chest X-ray score, APACHE II score, clinical pulmonary infection score, ECG, sputum culture, et al.The primary endpoints are pathogenic clearance rate and recovery rate. The secondary end point is adverse reaction rate.
A two-week cross-titration phase followed randomization when patients started treatment with Risperidone in a double-blind manner and were tapered off Thiothixene. A six-week double blind active treatment period followed. Target dose was 6mg/day or highest dose tolerated.
Eligibility criteria: Gastrointestinal disease or clinical symptoms related to colorectal cancer risk. Exclusion criteria consisted of age younger than 18 years, history of psychiatric illness, and preoperative radiotherapy.

Outcome measures: RC screening was carried out using a Tissue Resonance InterferoMeter probe (TRIMprobe) electromagnetic detector (Galileo Avionica, Turin, Italy), which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. No metallic objects were allowed on the patient and no electronic devices were admitted in the test area. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on the investigators previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U. The device lets the examination limited to the pelvis and we regarded the rectum cutoff within 15 cm from the anal verge.
The present invention relates to a monoclonal antibody which specifically recognizes c-Myc protein or a part of the protein; or a fragment thereof. In particular, the monoclonal antibody or a fragment thereof comprises one polypeptide sequence selected from the group consisting of the following polypeptide sequences. The monoclonal antibody is formed by a heavy chain and a light chain, wherein the heavy chain includes CDR1 region described as SEQ ID NO. 1, CDR2 region described as SEQ ID NO. 2, and CDR3 described as SEQ ID NO. 3, and the light chain includes CDR1 region described as SEQ ID NO. 4, CDR2 region described as SEQ ID NO.5, and CDR3 region described as SEQ ID NO. 6. The antibody of the present invention acts as antagonists reducing Myc-activities in various cancers, and thus may be chosen as an antibody candidate material for cancer treatment.
PURPOSE: To prevent secondary adhesion of a lipstick from occurring and to eliminate the change in texture of the lipstick by blending a water component with a specific perfluoropolyether and perfluoroalkyl phosphate diethanolamine salt and one or more of silica powder and or alumina powder. CONSTITUTION: Perfluoropolyether is shown in formula I and perfluoroalkyl phosphate diethanolamine salt is shown in formula II. Further, in formula I, R<1> to R<5> are the same or different and denote a fluorine atom, a perfluoroalkyl group or an oxyperfluoroalkyl group. (p), (q) and (r) denote an integer >=0 which gives 500-10000 molecular weight but the formula p=q=r=0 does not happen. In formula II, (n) denotes an integer of 6-18 and (m) denotes 1 or 2. A water-soluble polymer is contained in a water component. Furthermore, a perfluoroalkyl phosphate diethanolamine salt is contained at 0.1-10wt.% in the whole emulsified composition.
Patients with ulcerative colitis (UC) may undergo colectomy due to a variety of reasons, including medically refractory disease or dysplastic changes of the colon. Ileal-pouch anal anastomosis is often offered to these patients. Unfortunately the pouch commonly develops inflammation, known as pouchitis, which is the most common complication of this procedure and occurs in approximately 50% of patients, with the majority of these patients having multiple episodes.

Although the exact cause of pouchitis is not clear, it is felt that fecal bacteria may be implicated in the cause. Studies have demonstrated changes in the fecal contents of patients with pelvic pouches compared to those with end ileostomies, with higher concentrations of Bacteroides and stool anaerobes identified in those patients with pelvic pouches. Antibiotics are a mainstay of treatment for pouchitis, with randomized controlled trials demonstrating response rates of 70-85% to metronidazole or ciprofloxacin for treatment of acute pouchitis. Unfortunately, recurrent use of systemic antibiotics is associated with adverse events and development of antibiotic resistance.

Fecal Microbiota Transplantation (FMT) is the administration of the supernatant component of stool and water mixture from a healthy screened donor. The donors are screened for numerous infections and pathogens prior to being accepted as donors. FMT has been advocated for some colonic disorders; however it is primarily used in recurrent/refractory Clostridium difficile infections (CDI). A case series from McMaster of over 100 patients and have shown that approximately 90% of patients with recurrent CDI have been cured with FMT. The rationale is that the aberrant colonic microbiome can be replaced with a normal healthy microbiome from a donor. A similar rationale has been applied to ulcerative colitis, and a recent systematic review and meta-analysis conducted by the investigators demonstrated FMT is associated with improved clinical remission and endoscopic healing compared to placebo. It seems possible that changing the intestinal flora in patients with pouchitis could also return the mucosa to a healthy state.

The investigators have conducted the world's first randomized trial of fecal transplant therapy to determine its efficacy and safety in patients with active UC. The investigators found that fecal transplants given once per week for 6 weeks resolved the inflammation in 24% of patients with active UC compared to 5% with placebo. There has been no randomized control trial evaluating the efficacy of FMT for treatment of pouchitis. An initial case series of 8 patients did not find treatment with one administration of FMT via nasogastric administration to be associated with any improvement in clinical response. However a subsequent case series found improvement in 4 out of 5 patients with chronic pouchitis who had multiple FMT treatments over 3-4 weeks. The investigators will conduct a randomized trial at a single centre (McMaster University) comparing fecal transplant therapy (from a healthy donor) versus placebo for six weeks for induction of remission in patients with active pouchitis.
The invention provides a system and method of collecting, storing and managing laboratory test results of patients. In one embodiment the invention is directed towards collecting, storing and managing laboratory test results of patients taking an endothelin receptor antagonist (ERA). The system provides a way of securely collecting and tracking information from a plurality of patients, a plurality of laboratories, and a plurality of health care providers by use of a database. The method comprises receiving patient information from health care providers, receiving a laboratory test schedule for each patient, and laboratory tests needed for each patient. This data is entered into a central processing computer. The patients then go to any laboratory to have the monthly testing done due to the ERA prescription. The laboratory test data collected is sent to the central processing computer. The central processing computer can generate an automated report on the laboratory results and supply the results to the health care provider. Additionally, if no laboratory test data for the patient is entered into the central processing computer in accordance with the laboratory test schedule for the patient, the central processing computer will notify a call center which will call the patient, laboratory or health care provider informing them of the overdue laboratory test data.
Spirometry. Bronchodilator with Salbutamol. Induced sputum in \> 10 years of age using Sodium Chloride Inhalation. Multiple Breath Washout (MBW).
In the imiquimod and intramuscular vaccine arm, intervention consists in the topical application of a single bag of Aldara™ creme 5%, containing 12.5 mg of imiquimod, on a 16 cm2 square delimitated area on the non-dominant arm at the time of influenza vaccination. An intramuscular influenza vaccine preparations containing 15 μg of each of the three viral strains (Mutagrip®) will be administrated in the centre of the marked area after the imiquimod cream is fully absorbed.
PROBLEM TO BE SOLVED: To provide a sheet type patch, which can be percutaneously absorbed in a short time and is also effective for preventing drug abuse.SOLUTION: The present invention provides a percutaneous absorption method. The sheet-like patch comprises two mucosal adhesion layers (10 and 20). These two layers have a mucosal adhesion surface (40) on the outer surface. When applied to the inside of the cheek or under the tongue, a drug release from both mucosal adhesive surfaces. Thus, the drug can be percutaneously absorbed in a short time. The present invention further provides a patch for percutaneous absorption. The patch can be provided with an intermediate layer (50). When the drug is an abusable drug such as an opioid, an antagonist such as naloxone may be contained in the intermediate layer to prevent the antagonist from being percutaneously absorbed. Thus, it shows only an opioid analgesic effect. On the other hand, when dissolving and injecting the patch for the purpose of abuse, the opioid is invalidated by the antagonist.SELECTED DRAWING: Figure 3
PURPOSE:To prevent the nonuniformity and hardening defect of the resin of the molding taken out of a gypsum mold by coating a compsn. contg. a high polymer binder or high polymer film forming agent, light reflective pigment and a solvent as essential components to a gypsum pattern and drying the coating. CONSTITUTION:The high polymer binder or high polymer film forming agent which is used for the photopolymerizable separating agent is soluble in water, includes synthetic products, such as polyvinyl alcohol and natural products, such as gelatin. The high polymer binder or high polymer film forming agent which is soluble in oil includes thermoplastic synthetic high polymers, such as polyvinyl acetate, and natural products, such as colophonium. While pigments of a white system, such as titanium oxide, are mainly exemplified as the light reflective pigment, the difference in the reflective index regulated by the high polymer binder or high polymer film-forming agent and the solvent is preferably >=0.5. Water, acetone, toluene, etc., may be properly used so as to meet the high polymer binder high polymer film-forming agent as the solvent. The film of this separating agent is easily formed by coating this agent to the gypsum mold and drying the coating. The absorption of light by the color of the gypsum mold is eliminated and the effect of retarding the curing of the resin does not arise and, therefore, the post-hardening by a heat treatment is efficiently executed.
Factors and methods for disrupting or inhibiting the association of protomers of a multimeric protein are described. Such inhibition reduces the biological activity of the target protein, which is desirable in the case of certain physiological disorders. Particularly, novel neurotrophin antagonists are described. In one aspect of the invention, peptides that inhibit the association of protomers of a growth factor having a cysteine knot, such as a neurotrophin, aredescribed. In another aspect, the antagonist is bicyclic peptide preferably derived from the internal reverse turn region of a member of the structurally similar neurotrophin family including NGF, BDNF, NT-3, NT-4/5 and NT-6 and functional equivalents thereof. Generally, the antagonist comprises amino acids from positions 68-58 and 108-110 of a neurotrophin, in which the amino acid from position 68 is covalently bound to the amino acid from position 108 and theamino acid from position 58 is covalently bound to the amino acid at position 110 to form a bicyclic structure. In another aspect of the invention transition metal ions are provided for selectively altering the geometry of the receptor binding domains of neurotrophins which allows functionality and activity of the neurotrophins to be selectively reduced. For example Zn2+ alters the conformation of NGF rendering it unable to bind to p75NTR or TrkA receptors or to activate signal transduction and biological outcomes normally induced by thisprotein. Molecular modelling studies predict that Zn2+ binding to NGF will induce structural changes within domains of this neurotrophin which participate in the recognition of TrkA and p75NTR N. Ni2+ on the other hand selectively alters the conformation of NGF rendering it unable to bind to TrkA but does not affect binding to p75NTR Similar actions of Zn2+ are also observed with other members of the NGF family, suggesting a modulatory role for the metal ions in neurotrophin function.
Non-small cell lung cancer (NSCLC) survivor is increasing as developing early diagnosis and perioperative management. Despite multidisciplinary treatment, Surgery is the primary treatment option for cure in NSCLC. The patients with lung cancer who underwent surgery have limitation of pulmonary function and high risk of co-morbidities. Perioperative physical activity has been shown to reduce symptoms and prevent complications, improve long term quality of life after surgery. But validated exercise regimen has not been established for lung cancer patients. Therefore, Evidence-based guideline focusing on lung cancer after surgery is needed.
The endocannabinoid system, an important biological network for maintaining and balancing various functions of the human body, is involved in many physiological functions such as pain, emotion, learning and memory, etc. Among which the endocannabinoid receptors [including type I (CB1) and type II (CB2) receptors] play an important role in the regulation of pain and have become an important target in the mechanism research of acupuncture analgesia. CB1 is mainly distributed in the central nervous system, including the spinal cord, cerebral cortex, amygdala, insular cortex, and basal ganglia, etc. CB2 is mainly distributed in peripheral immune tissues, such as spleen, bone, skin, etc. In the central and peripheral nervous systems, acupuncture can activate CB1 and CB2 receptors respectively, which is involved in the transmission of central nociceptive signals and related transmitters as well as the peri-pheral pro-nociceptive inflammatory response, thereby alleviating the nociceptive hypersensitivity in animal models. In this paper, we systematically summarize the roles of the above mechanisms in different types of animal models (inflammatory pain, neuropathological pain, visceral pain, etc.), so as to provide new ideas for the study of the underlying mechanisms of acupuncture analgesia.
<P>PROBLEM TO BE SOLVED: To provide a stable liposome preparation having high effectiveness and comprising oxaliplatin.  <P>SOLUTION: This liposome preparation contains the oxaliplatin and is derivatized with a hydrophilic polymer and a ligand. Furthermore, a pharmaceutical preparation comprises the liposome preparation and is used for treating tumor. The liposome preparation is derivatized with the ligand. The ligand is preferably transferrin which promotes the uptake of a drug through a transferrin receptor expressed on a tumor cell surface into the tumor cell.  <P>COPYRIGHT: (C)2004,JPO
A urinary tract infection treatment medicine comprises 10-50g of fresh leaf of Plantain Herb, 10-200g of fresh shepherd's purse and 10-80g of fresh Herba Taraxaci. Leaf of Plantain Herb is sweet in taste and cold in nature, and has the efficacies of heat clearing, urination promoting, dampness excreting, diarrhea relieving, liver clearing and eyesight improving. Shepherd's purse is sweet in taste and neutral-cold in nature, has the efficacies of heat clearing, urination promoting, spleen harmonizing, liver calming and eyesight improving, and is mainly used to treat stranguria and chyluria. Herba Taraxaci is sweet-bitter in taste and cold in nature, and has heat clearing, detoxifying, inflammation eliminating and urination promoting effects. The above three medicines are combined to rapidly solve annoyance brought by urgent urination and frequent urination. The medicine is prepared through the following steps: washing collected fresh medicines to remove soil, putting the cleaned medicines in a marmite, adding 400ml of water, boiling, and cooling to a suitable temperature. Dried medicines accounting for 50% of the total mass of the fresh medicines are decocted to obtain a decoction, and the decoction can be drunk as a tea three times every day. A treatment course comprises 7 days.